Objective: Preterm neonates with candidemia frequently have persistently positive blood cultures, despite the use of conventional antifungal therapy. Our institutional treatment protocol for invasive candidiasis incorporates lipid complex amphotericin B as initial therapy with the sequential addition of fluconazole and high-dose micafungin (10 mg kg À1 ) every 48 to 72 h, if
Introduction
Neonatal candidiasis is associated with significant mortality and morbidity and high rates of neuro-developmental impairment on follow up. 1 Persistent candidemia has been reported to occur relatively frequently in premature infants. Among 320 extremely low birth weight infants from the NICHD Neonatal Research Network sites with invasive candidiasis documented with blood or spinal fluid cultures, more than half had >1 positive blood culture for Candida. The median duration of positive blood cultures after systemic antifungal treatment among survivors was 3 days and 10% survivors had persistent candidemia for 14 days or longer. 1 Despite its common occurrence, there are limited data on the risk factors and outcomes of persistent candidemia.
Persistent candidemia defined as longer than 5 days was reported in 52% of neonates in one study and was associated with an increased risk of endocarditis, although not with other complications or increased mortality. 2 Another study defined persistent infections as positive cultures >24 h after achieving target doses of amphotericin B (0.5 mg kg À1 day À1 ) or fluconazole (6 mg kg À1 day
À1
) and reported higher rates of focal complications and/or death from candidiasis. 3 Focal complications were found to be increased with the duration of persistence. 3 In the NICHD Neonatal Research Network study, antifungal therapy failure, defined as death within 14 days after initiation of antifungal therapy or a positive blood culture for Candida beyond this period was observed in 63 (26%) infants. A lower birth weight between 401 and 750 g and lack of enteral feeding were the identified risk factors for antifungal therapy failure. 1 Persistent neonatal fungemia in these reports occurred despite conventional therapy with amphotericin B, fluconazole or a combination. [1] [2] [3] Recent studies suggest that lower antifungal drug dosages used in neonates may explain the prolonged candidemia in this population. 4 Higher antifungal drug doses may be needed to achieve targeted systemic drug exposures. 5 The purpose of the current retrospective study is two-fold. First, was to compare the clinical profiles and outcomes of infants with candidemia refractory to conventional antifungals, who required addition of an echinocandin, in comparison to those who responded to conventional antifungals. Second, we describe the clinical and microbiologic outcomes of infants treated with micafungin at a dose of 10 mg kg À1 daily.
Methods
We performed a retrospective chart review of infants admitted to the Neonatal Intensive Care Units at Children's Hospital of Michigan and Hutzel Women's Hospital between January 2006 and December 2007, who had a positive blood culture for Candida and were treated with at least one dose of an antifungal agent. We identified infants with a positive blood culture for Candida and further used the pharmacy and discharge database (search keywords 'antifungal' and 'amphotericin B') to determine eligibility. The study was approved by the Institutional Review Board of the Human Investigation Committee of Wayne State University. In our center, we have implemented a standardized treatment protocol for candidiasis; lipid complex amphotericin B (5 to 7.5 mg kg day À1 ) is first line therapy and fluconazole (10 mg kg À1 day À1 ) and micafungin (10 mg kg À1 ) are sequentially added if cultures from a sterile site (either blood or spinal fluid) remain positive despite 48 to 72 h of therapy. The stated exceptions to this protocol are C. lusitaniae and C. krusei bloodstream infections, which are known to have a high resistance rate to amphotericin B and fluconazole, respectively. In these cases, micafungin is added after a single antifungal agent. Following diagnosis of fungal bloodstream infection, daily or every other day blood cultures are drawn until a minimum of three negative cultures are obtained. Other culture sites include the central line, spinal fluid, urine and endotracheal tube in ventilated infants. An ophthalmologic examination for fungal ophthalmitis and imaging studies such as renal ultrasounds and echocardiograms are routinely performed at the time of diagnosis and repeated weekly in case of persistent infection. Complete blood counts, blood urea nitrogen and serum creatinine and liver enzymes are routinely performed at least once a week and twice weekly if abnormal. In the current study, infants who continued to have positive blood cultures for Candida for 48 to 72 h despite amphotericin B and fluconazole and were then started on an echinocandin were classified as 'refractory' candidemia. Infants who responded to either one of the two initial antifungal agents were considered 'responders'. Demographic data such as gestational age, gender and details of the neonatal course including incidence and severity of respiratory distress syndrome, presence of patent ductus arteriosus requiring treatment, necrotizing enterocolitis and intracranial hemorrhage were collected. Data on medications (duration and type of antimicrobials, H2 blockers and steroids administered), hyperalimentation and central lines before the fungal infection were obtained.
Details of the fungal infection and clinical and microbiologic outcomes were abstracted. Results of imaging studies including ultrasounds and echocardiograms, performed for clinical purposes were noted. Laboratory results before initiation of and following micafungin treatment were collected to assess safety of the drug.
Since June 2006, in an attempt to decrease the incidence of invasive fungal infections, we adopted a protocol of targeted short-term fluconazole prophylaxis to very low birth weight infants at greatest risk for invasive fungal infections during periods of antibiotic administration. Targeted fluconazole prophylaxis was administered concomitantly with broad-spectrum antibiotics among high-risk preterm infants (birth weights less than 1500 g, less than 6 weeks old and with at least one additional risk factor such as a central line, hyperalimentation, lipids or endotracheal intubation). 6 Fluconazole prophylaxis was initiated when a decision was made to administer broad-spectrum antibiotics for longer than 48 h and was stopped when the anti-bacterials were discontinued. The duration of targeted fluconazole prophylaxis, if administered, was noted for each subject. If an infant developed invasive candidiasis when on fluconazole prophylaxis, fluconazole was stopped and the treatment protocol (with lipid complex amphotericin B) was initiated. In a few cases, at the discretion of the treating physician, fungal isolates were tested for sensitivity to antifungal drugs with standardized microbroth dilution assays. Details of antifungal drugs (dosing regimen and duration) and central lines were reviewed. Clinical and microbiological outcomes such as death, focal complications and duration to fungal clearance were abstracted.
SPSS software (version 14) was used to generate mean, s.d., median and range values for clinical variables. Descriptive statistical analyses were employed. The group of infants with candidemia responsive to conventional antifungals was compared with the group who required micafungin. Proportions and continuous variables were compared using Fisher's exact two-tailed test and t-test and categorical variables using w 2 test.
Results

Baseline characteristics
Among 450 very low birth weight infants screened, 29 (6.4%) were diagnosed with Candida bloodstream infection and received at least one dose of an antifungal. The cohort, as a whole, had a mean ( ± s.d.) gestation of 27.3 ( ± 3) weeks and birth weight of 943.9 g (±554). II) . Seven infants received targeted fluconazole prophylaxis, concomitantly with broad-spectrum antibiotics; four (21%) in the refractory group and three (30%) among the responders (P ¼ 0.45). The median (range) duration of fluconazole prophylaxis was 10 (7 to 21 days) days among infants with refractory candidemia and 5 days [4] [5] [6] [7] among the responders (P ¼ 0.63).
Characteristics of fungal infection
The identification of organisms, age at diagnosis, site of focal involvement, if any, duration of fungemia and antifungal treatment and clinical and microbiological outcomes are compared between the two groups in Table 2 . In the refractory group, C. glabrata was isolated in two cases and C. guillermondii and C. krusei in one patient each. There were two cases of recurrence in the refractory group, defined as positive culture with the same species after three or more negative cultures while on treatment.
Mean duration of ventilation and oxygen therapy was comparable in the two groups. Nine (47.4%) infants in the refractory group survived, in contrast to eight (80%) in the responder group, although this was not statistically significant (P ¼ 0.13). Among the 12 infants who died, fungemia was a possible or proven cause of death in nine infants. As expected, the duration of fungemia and Micafungin therapy of refractory neonatal candidemia G Natarajan et al duration to sterilization after initiation of antifungals were significantly greater in the refractory group of infants. Drug sensitivities were performed in three infants with C. parapsilosis infection; the minimum inhibitory concentrations for fluconazole was 1.5 mcg ml À1 , for amphotericin B varied from 0.75 to 1 mcg ml
À1
and for caspofungin was 1 mcg ml À1 in two and 3 mcg ml À1 in one case.
High-dose micafungin
Micafungin was administered at a dose of 10 mg kg À1 intravenous daily. Laboratory results such as blood urea nitrogen, serum creatinine, liver enzymes and serum bilirubin were compared just before and on completion of micafungin therapy (Table 3) . Micafungin was initiated at a median time of 6.5 (range, 2 to 24 days) days after the first antifungal. The median duration of micafungin was 15 (range, 2 to 51 days) days. Among the 12 infants in the refractory group who achieved microbiogical clearance, the median duration to sterilization after addition of micafungin was 2.5 (range, 1 to 35 days) days. There were no direct adverse effects from the medication. There was a statistically significant increase in aspartate aminotransferase (AST) following micafungin therapy; mean ( ± s.d.) 55 ( ± 39) to 94 ( ± 56) U l À1 , P ¼ 0.001 whereas blood urea nitrogen, serum creatinine, alanine aminotransferase, alkaline phosphatase and bilirubin levels did not alter significantly. Among micafungin-treated infants, renal failure (defined as oliguria with a serum creatinine >1 mg per 100 ml) occurred pre-terminally in six infants and resolved in one infant. Hepatic impairment defined as AST/alanine aminotransferase >180 was noted in two infants, although after completion of micafungin therapy.
Discussion
In a homogenous cohort of infants with Candida bloodstream infections treated using a standardized antifungal protocol, we found that the duration of preceding antibiotic use and frequency of non-albicans fungal infection were significantly higher and nutritive enteral feeding less common among infants refractory to conventional antifungals. Despite the use of high-dose micafungin as a third line agent, fungal clearance and survival rates were dismal in the group of infants with refractory candidemia. This is the first report of clinical outcomes related to the use of micafungin at a high dose in a cohort of premature infants with invasive candidiasis.
Previous published data on risk factors for development of refractory candidemia are conflicting. Our finding of an association with duration of antibiotics and non-albicans species have not been previously reported but are certainly plausible. In an adult study, C. glabrata species was associated significantly with persistent fungemia on multivariate analyses. 7 Similarly, previous use of broad-spectrum antibiotics and in the 7 days before positive blood culture have been shown to be associated with candidiasis in extremely preterm infants. 8 It has been speculated that a longer duration of antibiotics may lead to more intestinal fungal Abbrevations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen. RF: Renal failure defined as oliguria (<1 ml kg À1 h À1 over >16 h) and serum creatinine >1 mg per 100 ml. HI: Hepatic impairment defined as AST/ALT >180 U l À1 .
colonization, a larger fungal burden and consequently, a higher risk of invasive infection. This may well be the reason that infants with longer duration of antibiotics develop Candida bloodstream infections that are difficult to eradicate with antifungal therapy. Therapy of neonatal candidiasis traditionally involves amphotericin B and fluconazole. Amphotericin B is a drug of the polyene class which binds to ergosterol in the fungal cell membrane, causing alterations in membrane function and leakage of cellular contents. 9 Fluconazole also targets the fungal cell membrane function by inhibiting the 14 a demethylation of lanosterol in the ergosterol biosynthetic pathway. 9 The echinocandins are emerging therapeutic options for persistent candidemia, albeit with limited pharmacokinetic and clinical data in neonates. 10 The antifungal mechanism is through the inhibition of the synthesis of b1, 3 glucan, a polysaccharide backbone of the fungal cell wall. Microbiological efficacy of caspofungin in infants with invasive candidiasis unresponsive to conventional antifungals has been reported in two previous case series. 11, 12 The international open-label clinical trial of micafungin (1 to 2 mg kg À1 daily dose) included 11 neonates, one of whom was a 'de-novo' fungal infection and the rest efficacy failures (candidemia with no response despite five or more days of systemic antifungals). 13 Eight neonates achieved a complete response, defined as clinical and microbiologic resolution. Another phase I single dose sequential dose trial investigated three doses of micafungin (0.75 mg kg À1 , 1.5 mg kg À1 and 3 mg kg À1 ) in 18 premature infants weighing >1000 g and 0.75 mg kg À1 dose in five preterm infants with weights <1000 g.
14 Micafungin is shown to have a shorter half life (8 h) and more rapid rate of clearance (39 ml h À1 per kg) in premature infants, compared with published data in older children and adults. The authors suggested that higher doses of 5 to 7 mg kg À1 in neonates >1000 g may approximate the area under the curve drug exposure of doses used in adults with clinical efficacy. A subsequent case report described successful treatment of cutaneous aspergillosis in an extremely low birth weight preterm infant in whom micafungin was administered at a dose of 8 mg kg À1 every 24 h for 6 weeks and a pharmacokinetic profile similar to adults and older children receiving 3 mg kg À1 daily achieved. 15 More recently, a multi-dose open-label pharmacokinetic study evaluated a dosing regimen of 15 mg kg À1 micafungin every 24 h for 5 days in 12 preterm neonates and reported that the clearance and area under the curve corresponded to approximately 5 mg kg À1 dosing in adults. 16 Data on clinical efficacy and safety of micafungin at these higher doses are lacking.
In our small case series, micafungin showed disappointing efficacy, with about 63% sterilization and less than 50% survival. This may be explained by a combination of two factors: our cohort of extremely preterm infants and our use of micafungin as a third line 'last-resort' agent. Infants in our study had multiple co-morbidities of prematurity and an extremely high incidence of respiratory distress syndrome, necrotizing enterocolitis and sepsis. Micafungin was added, only after persistent positive cultures despite dual antifungal coverage. Among adults, reported response rate for micafungin alone in the efficacy failure group was considerably higher at 76% (55 to 91), whereas micafungin with amphotericin B were efficacious in 80% (52 to 96) cases and triple therapy in 85.7% (42 to 100) cases (13) . A clear dose-response relationship has not been demonstrated for micafungin in adults. In the international open-label micafungin trial, complete or partial response was achieved in 12 of 16 (75%) patients at a daily dose of <50 mg and in 90 to 92% patients treated with >75 to 150 mg daily dose. 13 The small number of patients treated with even higher doses, however, had a lower response rate, perhaps because these were the most ill patients. 17 In another small (n ¼ 28) adult study, a comparison between two groups treated with differing initial doses (< and X2.25 mg kg À1 day À1 ) revealed overall clinical response of 86%. 18 There was no difference in the 30-day attributable mortality, although the duration to clinical response was significantly shorter in the high-dose group (21 ± 4.6 vs 16.9 ± 3.6; P ¼ 0.02). The doses used in our study, while higher than adult doses on a per kilogram basis, were intended only to be in the therapeutic range.
While there were no direct adverse effects related to micafungin, mean AST values showed a statistically significant increase at the end of treatment. The values are not clinically significant; however, and a three-fold elevation of AST occurred only in a minority of patients. It is also highly likely that candidemia per se may have induced hepatic inflammation, resulting in derangement of liver function. Since so many infants in the micafungin-treated group died, further prospective trials are needed to establish the overall efficacy and safety of this dose of micafungin in this population. The weaknesses of the current report are its retrospective nature, small sample size and lack of pharmacokinetic data and consistent susceptibility testing of fungal isolates.
Clinical treatment failure or 'refractory' candidemia is the result of a complex interaction between different Candida species, their diverse virulence traits and the host. 19 Recent genome-centered approaches to better understand the mechanisms of antifungal resistance and efforts to identify novel targets for development of future antifungals and to minimize the evolution of resistance are critical early steps in combating refractory candidemia. 19 In conclusion, given its frequent occurrence and its association with mortality and long-term sequelae, refractory candidiasis in preterm infants remains an under-investigated area. Early diagnosis, robust measurement of antifungal resistance and optimal therapeutic regimens with adequate rational doses of a combination of antifungal drugs may improve clinical outcomes in this population. Further prospective studies to evaluate standardized antifungal regimens and the impact of early initiation of echinocandins, alone or in combination are urgently needed.
